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1. Preiswerk B, Rudiger A, Fehr J, Corti N. Experience with daptomycin daily dosing in ICU 
patients undergoing continuous renal replacement therapy. Infection. 2013 Apr;41(2):553-7 
2. Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, Müller D, Béchir M, Maggiorini M. 
Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal 
replacement therapy. Chemotherapy. 2013;59(2):143-51 
3. Reiber C, Senn O, Müller D, Kullak-Ublick G.A. Corti N. Therapeutic Drug Monitoring of 
Daptomycin: a Retrospective Monocentric Analysis. Ther drug monitoring (accepted for 
publication) 
4. Curkovic I, Lüthi B, Franzen D, Ceschi A, Rudiger A, Corti N. Trimethoprim/Sulfamethoxazole 
pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. Ann 
Pharmacother. 2010 Oct;44(10):1669-72 
5. Meloni M*, Corti N*, Müller D, Henning L, Weber R, Fehr J. Cure of tuberculosis despite 
concentrations of antituberculosis drugs below published reference ranges: A retrospective 
analysis. Accepted for publication by Swiss Medical Weekly. 
 
 
1.2. Three publications of high scientific value, not discussed in the “kumulative 
Habilitationsschrift” 
 
1. Pfister P*, Corti N*, Hobbie S, Bruell C, Zarivach R, Yonath A, Böttger EC. 23S rRNA base 
pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance 
mutation 2058A-->G. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5180-5 
2. Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, Russmann S, Corti N, Wüthrich RP. 
Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism 
after renal transplantation. Am J Transplant. 2008 Apr;8(4):803-10.  
3. Corti N, Heck A, Rentsch K, Zingg W, Jetter A, Stieger B, Pauli-Magnus C. Effect of ritonavir 
on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction 
study in healthy volunteers. Eur J Clin Pharmacol. 2009 
 
 
*denotes equal contribution of the authors 
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2. Background to the presented work 
2.1. Parameters describing efficacy of anti-infective agents 
The individual dose response relationship of an anti-infective agent is the sum of a complex interaction 
of several factors. It is determined by the characteristic pharmacodynamic profile of an antimicrobial 
which is based in one part on the minimal inhibitory concentration (MIC) 1. MIC is the most commonly 
used pharmacodynamic parameter to describe efficacy of an antibiotic towards a bacterial strain and is 
determined as the lowest antimicrobial concentration that inhibits growth of microorganisms in vitro. 
Defined by the relationship between optimal antimicrobial drug exposure pattern versus MIC, mainly 
two pharmacodynamic indices have been used to determine optimal dosing strategy 2. For anti-
infectives with a so called time-dependent effect, maximum efficacy can be reached by keeping 
antimicrobial serum concentration above MIC for a sufficient time period within the dosing interval 
(T>MIC). This is the case for beta-lactam antibiotics such as carbapenems or penicillins. For anti-
infectives with a concentration-dependent effect such as daptomycin or aminoglycosides, magnitude 
of drug exposure in relation to MIC defines maximum efficacy. Peak plasma concentration (Cmax) and 
area under the curve (AUC) are pharmacokinetic (PK) variables that describe maximum drug 
exposure best. These variables are put in relation to MIC (Cmax/MIC and,or AUC24h/MIC) to 
determine optimal ratio. In concentration –dependent antibiotics higher doses and consecutively 
higher plasma concentrations of anti-infectives correlate with a better bactericidal effect. 
            
       
 
Individual pharmacokinetics of a drug i.e. absorption, distribution, metabolism and elimination define 
drug exposure in plasma and finally at target site. Organ function and severity of disease can influence 
pharmacokinetics of a drug leading to high inter-and intra-individual variability with the risk of 
suboptimal or excessive antimicrobial plasma concentration. Inadequate drug exposure not only bears 
the risk of therapeutic failure but also compromises outcome by selection of resistant strains3. Regular 
determination of drug plasma concentration i.e. therapeutic drug monitoring (TDM) during anti-infective 
treatment is a well-established tool to guide anti-infective dosing for antibiotics such as vancomycin or 
Fig.  PK/PD indices associated with the efficacy of the antibiotics 
Ref: Asín-Prieto et al. J Infect Chemotherapy 2105 
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aminoglycosides. For newer antibiotics like daptomycin and some older reemerging antibiotics like 
colistin routine TDM has not yet been established although knowledge on optimal drug exposure can 
be estimated based on animal data. To overcome PK variability and to find optimal dosing 
requirement, an individualized antibiotic dosing strategy has been advocated based on determination 
of antimicrobial plasma drug concentrations4. 
 
2.2. Anti-infective dosing in critically ill patients and in patients with acute renal failure 
undergoing continuous replacement therapy 
Severe sepsis and septic shock are frequent reasons for administration of antimicrobials on intensive 
care units (ICU). Septic shock has a mortality as high as 80%, therefore administration of adequate 
antibiotic doses already in the first hours but also in the course of treatment is important to improve 
survival5.  However, optimal antibiotic dosing is a challenge in critically ill patients. This is in part due to 
altered and variable drug pharmacokinetics which makes it difficult to apply dosing recommendations 
derived from healthy volunteers. Capillary leak in septic patients leads to an increase in volume of 
distribution, hypoalbuminemia increases free drug fraction, changes in intestinal motility and 
administration of enteral feeding can affect drug absorption6 and rapid changes in organ function can 
increase or decrease drug clearance 4, 7.  
Acute renal failure (ARF) affects approximately 35% of ICU patients and continuous renal replacement 
therapy (CRRT) such as continuous veno-venous hemodialysis or continuous veno-venous 
hemo(dia)filtration is often required8. For a large number of antimicrobials that are predominantly 
eliminated by the kidneys dose adaptation is necessary in patients with compromised renal function 
and also in patients undergoing renal replacement therapy9. Dosing recommendations are usually 
based on specific studies investigating PK in patients with different degrees of chronic renal failure 
with or without intermittent hemodialysis (IHD)10. IHD is performed twice or three times per week over 
3-4 hours and drug removal is limited to hemodialysis sessions. In contrast CRRT provides constant 
solute and daily drug removal over 24 hours which goes along with a more effective drug clearance 
and requires higher daily doses compared to IHD11. Therefore dosing recommendations derived from 
IHD studies cannot be applied to patients undergoing CRRT.  Although studies investigating anti-
infective pharmacokinetics in patients undergoing CRRT have increasingly been published in recent 
years12, 13, PK data and dosing recommendations for most of newer and older reemerging anti-
infectives were lacking until recently. Consequently antimicrobial dosing is often inadequate or even 
under dosed in this vulnerable patient population with complicated infections. Therefore knowledge 
about the optimal dose in CRRT is crucial14.  
 
2.3. Daptomycin in critically ill patients undergoing continuous renal replacement therapy 
Daptomycin is the first lipopeptide antibiotic and exhibits a rapid concentration-dependent bactericidal 
action against Gram-positive organisms including methicillin-resistant Staphylococcus aureus or 
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vancomycin-resistant Enterococcus spp.15. Based on animal data, the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) suggests a mean AUC24h/MIC target of 438 of total 
drug for bacteriostatic effect against susceptible S.aureus strains (MIC <0.5mg/l) and for a bactericidal 
effect even a mean AUC24h/MIC target of 1061 is recommended16, 17.This exposure translates in a 
minimal plasma AUC24h of 400mg*h/l for a bactericidal effect. As Enterococci exhibit a higher 
daptomycin MIC even higher daptomycin plasma concentrations are probably needed. Although 
routinely determination of daptomycin plasma concentrations for therapy monitoring has not yet been 
established, analytical method for daptomycin measurement has been established at our institution 
since 2009 and is increasingly being used.  Daptomycin is highly protein bound (90–96%) and is 
mainly eliminated by the kidneys with a mean renal clearance of 10ml/min. About 30% is presumably 
metabolized in the kidneys and excreted as metabolites and only 5% is excreted in the feces18 . In S. 
aureus bloodstream infections, including those in patients with right sided endocarditis caused by 
methicillin-resistant and methicillin-susceptible strains, the labeled dose is 6 mg/kg every 24 h. As 
accumulation occurs in patients with renal failure, the dosing interval is prolonged to 48 h in patients 
with severe renal insufficiency (creatinine clearance <30 ml/min) or intermittent hemodialysis (IHD) 19. 
However, official daptomycin dosing recommendations for patients undergoing CRRT are currently not 
available19. This results in differing dosing regimens in CRRT patients with risk of underdosing 
especially in cases where the dosing regimen for patients with severe renal failure i.e. q48h is applied.  
On one hand the high plasma protein binding (90–96 %) of daptomycin suggests that the drug may 
not be extensively removed by CRRT. However,  the first PK study that was conducted in a CRRT 
model with bovine plasma enriched with daptomycin using filtration rates of 35 ml/kg/h or higher, 
showed that daptomycin CRRT clearance was comparable or even higher than clearance in patients 
with normal renal function (7–10 ml/min)20. Optimal daptomycin in critically ill patients undergoing 
CRRT has been a matter of debate. Some authors advocate a dose of 8mg/kg once every 48 hours 21, 
22 in order to reach sufficiently high peak concentrations and to avoid high daptomycin trough 
concentrations and accumulation. Others found very low plasma concentration at doses of 4mg/kg 
every 24h and recommend a higher dose administered once daily to ensure efficacy 23.  Based on the 
findings of the model study we postulated that a daptomycin dose reduction or a prolongation of the 
dosing interval  is not necessary in patient undergoing CRRT. We conducted two studies to investigate 
daptomycin pharmacokinetics and dosing in CRRT.  
 
2.4. Therapeutic drug monitoring in anti-tuberculosis treatment 
TB treatment is a major challenge for patients, physicians and health care systems. First line 
antibucerculosis drugs such as isoniazid, rifampicin, pyrazinamide and ethambutol are administered 
over the first 2 month in pulmonary TB. Isoniazid and rifampicin are then continued over 4 month24 . A 
well-conducted six month TB treatment is effective: cure rates of >95% can be achieved in pulmonary 
TB under directly observed therapy (DOT) 25-27. Several factors complicate TB treatment. Case series 
28, 29 and non-controlled clinical studies 30-34 indicate that comorbidities such as HIV infection and 
chronic diarrhoea might increase the risk of poor absorption of antituberculosis drugs (ATD). In vitro 
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data show a clear concentration-dependent effect on Mycobacterium tuberculosis for all first-line ATD 
drugs35, 36, consequently higher drug concentrations levels should correlate with antituberculosis 
efficacy and low levels with therapeutic failure. In this context treatment guidance through therapeutic 
drug monitoring (TDM) has been advocated by some authors37, 38. However reference ranges for ATD 
plasma concentrations published so far are based on PK studies in healthy volunteers or Tbc-patients 
and represent peak drug concentrations usually reached under standard dosing conditions39 40. 
Moreover these ranges do not take into consideration a possible synergistic effect of ATD. So far there 
is no clear evidence that ATD serum concentrations below these reference ranges are associated with 
treatment failure. 
Mostly retrospective data support that slow response to treatment, prolonged infectiousness, 
emergence of drug resistance and higher rates of relapse or treatment failures in Tbc- infected 
patients might be related to low serum concentrations 32, 34, 38, 41-46. However two clinical studies that 
have investigated ATD concentrations in relation to reference ranges and clinical outcome 
prospectively found an association of reduced efficacy only with low pyrazinamide plasma levels42, 47. 
Due to the heterogeneity of study design these results are difficult to interpret, therefore additional 
clinical data are needed to define ideal sampling time and true therapeutic range of ATD.  
 
3. Discussion of the selected publications 
3.1. Experience with Daptomycin Daily Dosing in ICU Patients Undergoing Continuous Renal 
Replacement Therapy 
 In a first pilot study, we retrospectively compared daptomycin plasma peak and trough concentrations 
that were measured routinely between May 2008 and December 2010 in 7 critically ill patients with 
and in 4 patients without CRRT exposed to a once-daily daptomycin regimen.  Patient characteristics 
and microbiological data, including minimum inhibitory concentrations (MICs), if available, were 
additionally collected from the patient charts. In CRRT patients, daptomycin plasma concentrations 
were in the range of those patients with normal or mildly impaired renal function. No drug 
accumulation was detected in CRRT patients with once-daily daptomycin dosing. Peak and trough 
plasma concentrations showed a high intra- and inter-patient variability in both groups. No correlation 
was found with dose per kg body weight or the CRRT effluent flow rate. When doses of 4 mg/kg were 
used, Cmax was in the lower range of values measured in healthy volunteers at the equivalent dose 
and at daptomycin doses of 6 mg/kg they were substantially lower compared to equivalent doses in 
healthy volunteers48, 49. Microbiological eradication was successful in 8 of 11 patients. Two of three 
patients with unsuccessful microbiological eradication and fatal outcome had an Enterococcus faecium 
infection. 
In this study we found a first evidence for our assumption that a full daptomycin dose with a once daily 
administration could be adequate for patients with acute renal failure undergoing CRRT. Furthermore 
the data indicate that with the labelled dose of 6mg/kg for S.aureus bacteraemia could even lead to 
underdosing in individual cases especially in patients with an enterococcal infection. In view of the 
high variability of daptomycin exposure independent of dose and CRRT modality used, a routinely 
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measurement of daptomycin plasma concentrations to optimize daptomycin dosing might be 
warranted.  
 
3.2. Pharmacokinetics of Daily Daptomycin in Critically Ill Patients Undergoing Continuous 
Renal Replacement Therapy 
This prospective PK study in critically ill patients with acute renal failure undergoing CRRT was 
conducted with the aim to determine daptomycin PK, daptomycin clearance in dependence of the 
CRRT filter and effluent rate used and to formulate a dosing recommendation. Patients with an 
established first-line antibiotic treatment for proven or suspected Gram-positive infection were included 
and in addition 6mg/kg daptomycin i.v. was administered every 24h for study purposes over 5 days. 
Extensive pharmacokinetic blood sampling was performed on day 1, 3 and 5. We found that 
daptomycin removal in CRRT was comparable to daptomycin clearance in normal renal function and 
no drug accumulation occurred with the once- daily dosing. The mean AUC24h of  667.4 mg·h/l in 
these patients was in the range of AUC24h observed in healthy volunteers and translates into the 
AUC24h/MIC target of >1061 mg·h/l for a bactericidal action in S.aureus strain with a MIC<1mg/l17. 
However, in contrast to healthy volunteers a high variability of daptomycin exposure was observed 
with daptomycin AUC24h as low as 265 mg*h/l in individual cases. In case of S.aureus MIC >1mg/l or 
in enterococcal infections low daptomycin concentrations theoretically bear the risk of therapeutic 
failure. We further observed a strong correlation of AUC24h to peak and especially trough 
concentrations (R2=0.94, p <0.001) indicating that daptomycin trough concentration is a valuable 
parameter for therapeutic drug monitoring in critically ill patients undergoing CRRT. 
In conclusion a once daily dosing of at least 6mg/kg seems adequate in the majority of ICU patients 
with renal failure undergoing CRRT. However, in certain patients higher daily doses might be required. 
In view of the high variability of daptomycin exposure in this patient population determination of 
daptomycin trough concentrations is an important tool to optimize daptomycin dose in dependence of 
individual PK parameters and specific MIC of infecting organism.   
 
3.3. Therapeutic Drug Monitoring of Daptomycin: a Retrospective Monocentric Analysis 
The efficacy of labelled daptomycin doses of 4mg/kg once daily in the treatment of complicated skin 
and soft tissue infections (cSSTI) and 6mg/kg for blood stream infections including those with right-
sided endocarditis caused by methicillin-resistant S.aureus and methicillin-susceptible strains was 
proven in two pivotal trials 50, 51. Daptomycin use and efficacy in other types of infection has mainly 
been investigated in retrospective studies52, 53. The available data indicates that doses up to 12mg/kg 
have been administered safely and have been recommended for severe and difficult to treat Gram- 
positive infections, such as bacteremia, infective endocarditis and osteomyelitis54. The focus in all 
these studies was to investigate specific dosing regimen and outcome. However daptomycin plasma 
concentrations were not determined therefore the knowledge about effective drug exposure in relation 
to efficacy and its interindividual variability is lacking. 
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Daptomycin plasma concentration measurement was established at the University Hospital of Zurich 
in January 2009 and has increasingly being used since then. The objective of this retrospective study 
was to describe variability of daptomycin plasma concentrations and to determine the main factors 
associated with excessive or low drug exposure. Patients with at least one determination of 
daptomycin plasma concentration in the period of 2009-2012 were eligible. A total of 332 daptomycin 
plasma concentrations were determined in 86 patients. We tested clinical and demographic data such 
as daptomycin dose and dose interval, weight, different categories of renal function or renal 
replacement therapy and their association with daptomycin exposure by a multilevel linear regression 
analysis. We found that only 28% (P<0.005) of Cmin variability and 8% (P=0.08) of Cmax variability 
was explained by the factors included in the analysis. These findings reveal that daptomycin plasma 
concentrations are often unpredictable and underline the usefulness of daptomycin therapeutic drug 
monitoring especially in critically ill patients.   
 
3.4. Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous 
venovenous hemodiafiltration 
 
Trimethoprim/sulfamethoxazole (TMP/SMX) is the drug of choice for the treatment of Pneumocystis 
jirovecii pneumonia (PJP) and for infections with the opportunistic bacillus Stenotrophomonas 
maltophilia. Both types of infection are found predominantly in immunocompromised patients and in 
patients with multiple comorbidities. Especially PJP-patients are most often hospitalized at the 
intensive care unit and in cases of severe disease acute renal failure can occur and CRRT is required. 
As TMP and SMX are excreted in part by the kidneys as unchanged drugs (50–70% and 10–30%, 
respectively), renal dysfunction leads to diminished elimination. Dose reduction and/or prolongation of 
dosing interval are therefore recommended in patients with renal failure55, 56. However, until this 
investigation was done no data or labelled dosing recommendations were available concerning 
TMP/SMX dosing in CRRT patients. We therefore determined pharmacokinetics and CRRT clearance 
in two anuric critically ill patients undergoing continuous veno-venous hemodiafiltration (CVVHDF) 
treated with intravenous TMP/SMX in order to derive a dosing recommendation. In both patients 
TMP/SMX dosage was reduced to 50% of the standard dose on starting CVVHDF. We found that both 
TMP and SMX were cleared to a significant degree by CVVHDF in our patients, with haemodialysis 
probably contributing to a greater extent to their elimination compared to hemofiltration alone. TMP-
ClCVVHDF was in the lower range of the renal clearance reported for normal renal function and SMX 
ClCVVHDF even significantly exceeded normal renal clearance. TMP peak concentrations were in the 
lower range and SMX peak concentrations were one third of those described and recommended in the 
literature57, 58. We therefore concluded that in critically ill patients undergoing CVVHDF, TMP and SMX 
dose reduction is not required to ensure adequate exposure. Based on these findings dosing 
recommendations in house were revised and full dose TMP/SMX is now administered in CRRT 
patients at our institution. This publication has served as reference article concerning TMP/SMX 
dosing in CRRT during the last years. Our data has been supported meanwhile by a CRRT model 
study and a case report investigating PK in extended dialysis 59, 60.   
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3.5. Cure of tuberculosis despite concentrations of anti-tuberculosis drugs below published 
reference ranges: A retrospective analysis 
Based on the fact that therapeutic reference ranges of anti-tuberculosis drug (ATD) are not defined, 
we retrospectively investigated the frequency of ATD concentrations below reference ranges in TB 
patients with therapeutic drug monitoring (TDM) during 2010 to 2012 at our institution. Clinical and 
microbiological outcome data were additionally evaluated. Maximum ATD concentration was 
estimated (eCmax) by assessing the highest value during a sampling period, in which about half of 
ATD concentrations were determined 2h after drug intake. eCmax was categorized into 3 groups:  
“within the reference range”, “low” and “very low”. In total we analysed drug concentrations from 175 
serum samples collected from 17 patients. In all but one patient (94%), at least one eCmax value was 
below the reference range. Overall eCmax was below the reference range in 78% of INH, 90% of 
RMP, and 50% of RFB measurements and in 30% of PZA and EMB determinations. 57% and 50% of 
all INH and RIF levels were categorized as “very low”.  In 7 of 17 patients INH and RMP levels were 
concurrently low or very low. However, 16 of 17 (94%) patients completed therapy and were cured 
based on WHO guidelines. Our study underlines the need to validate whether the reference ranges 
published by Peloquin, and widely used ever since, represent reliable therapeutic target 
concentrations that correlate with the TB treatment outcome in the clinical setting. Our data suggest 
that the therapeutic ranges for INH and RMP might be below the suggested ranges especially when 
combination treatment is used. Based on these finding a large-scale prospective PK and outcome 
study has been set up and is now ongoing in Uganda with the aim to investigate the association 
between serum concentrations of ATD and tuberculosis treatment response in HIV-TB-co-infected 
individuals (clinicaltrials.gov - NCT01782950). 
 
 
4.  Value of presented work 
With the results of the discussed studies we were able to suggest an optimized dosing regimen of two 
antibiotics in critically ill patients with severe infections undergoing renal replacement therapy. This 
has major implications for the avoidance of under dosing with the risk of treatment failure in this 
susceptible patient population. We additionally for the first time present an approach for daptomycin 
drug monitoring in patients undergoing CRRT by demonstrating a clear correlation between trough 
levels and drug exposure. Furthermore, we provided insights into the validity of reference ranges of 
anti-tuberculosis drugs which offers rational for further investigations.  
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